The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Cell Death

Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407

Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

Vaux, D., Cory, S., & Adams, J. (1988) · Nature · doi:10.1038/335440a0 · Cited by 3,355

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713

Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL

Zha, J., Harada, H., Yang, E., Jockel, J., & Korsmeyer, S. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81382-3 · Cited by 2,578

PUMA, a Novel Proapoptotic Gene, Is Induced by p53

Nakano, K., & Vousden, K. H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00214-3 · Cited by 2,315

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992

Interleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase Akt

Peso, L. D., González-Garcı́a, M., Page, C., Herrera, R., & Nuñez, G. (1997) · Science · doi:10.1126/science.278.5338.687 · Cited by 1,797

Involvement of the bcl -2 Gene in Human Follicular Lymphoma

Tsujimoto, Y., Cossman, J., Jaffe, E. S., & Croce, C. M. (1985) · Science · doi:10.1126/science.3874430 · Cited by 1,787

Cloning of the Chromosome Breakpoint of Neoplastic B Cells with the t(14;18) Chromosome Translocation

Tsujimoto, Y., Finger, L. R., Yunis, J. J., Nowell̀, P. C., & Croce, C. M. (1984) · Science · doi:10.1126/science.6093263 · Cited by 1,769

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605

Bid, Bax, and Lipids Cooperate to Form Supramolecular Openings in the Outer Mitochondrial Membrane

Kuwana, T., Mackey, M. R., Perkins, G. A., Ellisman, M. H., Latterich, M., Schneiter, R., Green, D. R., & Newmeyer, D. D. (2002) · Cell · doi:10.1016/s0092-8674(02)01036-x · Cited by 1,513

Proapoptotic Bcl-2 Relative Bim Required for Certain Apoptotic Responses, Leukocyte Homeostasis, and to Preclude Autoimmunity

Bouillet, P., Metcalf, D., Huang, D. C. S., Tarlinton, D. M., Kay, T. W. H., Köntgen, F., Adams, J. M., & Strasser, A. (1999) · Science · doi:10.1126/science.286.5445.1735 · Cited by 1,504

Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer

Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495

The BCL-2 Family Reunion

Chipuk, J. E., Moldoveanu, T., Llambi, F., Parsons, M. J., & Green, D. R. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.025 · Cited by 1,476

p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa

Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327

PUMA Induces the Rapid Apoptosis of Colorectal Cancer Cells

Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W., & Vogelstein, B. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00213-1 · Cited by 1,289

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

Certo, M. V., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S. J., Armstrong, S. A., & Letai, A. G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.027 · Cited by 1,278

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized

van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,271

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-x L , but not Bcl-2, until displaced by BH3-only proteinsPreprint

Willis, S. N., Chen, L., Dewson, G., Wei, A. H., Naik, E., Fletcher, J. I., Adams, J. M., & Huang, D. C. S. (2005) · Genes & Development · doi:10.1101/gad.1304105 · Cited by 1,236

bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation

McDonnell, T. J., Deane, N., Platt, F. M., Nunez, G., Jaeger, U., McKearn, J. P., & Korsmeyer, S. J. (1989) · Cell · doi:10.1016/0092-8674(89)90174-8 · Cited by 1,213

Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation

Cleary, M. L., Smith, S. D., & Sklar, J. (1986) · Cell · doi:10.1016/0092-8674(86)90362-4 · Cited by 1,212

BH3 Domains of BH3-Only Proteins Differentially Regulate Bax-Mediated Mitochondrial Membrane Permeabilization Both Directly and Indirectly

Kuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., & Newmeyer, D. D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.003 · Cited by 1,185

Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18

Bakhshi, A., Jensen, J. P., Goldman, P., Wright, J. J., McBride, O. W., Epstein, A. L., & Korsmeyer, S. J. (1985) · Cell · doi:10.1016/s0092-8674(85)80070-2 · Cited by 1,177

Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death

Henderson, S., Rowe, M., Gregory, C. D., Croom-Carter, D. S. G., Wang, F., Longnecker, R., Kieff, E. D., & Rickinson, A. B. (1991) · Cell · doi:10.1016/0092-8674(91)90007-l · Cited by 1,166

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

Konopleva, M. Y., Contractor, R., Tsao, T., Samudio, I. J., Ruvolo, P. P., Kitada, S., Deng, X., Zhai, D., Shi, Y.-X., Sneed, T. B., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.006 · Cited by 1,043

Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis

Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011) · Genes & Cancer · doi:10.1177/1947601911408889 · Cited by 1,033

Programmed Anuclear Cell Death Delimits Platelet Life Span

Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031

Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis

Yin, X.-M., Wang, K., Gross, A., Zhao, Y., Zinkel, S., Klocke, B., Roth, K. A., & Korsmeyer, S. J. (1999) · Nature · doi:10.1038/23730 · Cited by 1,004

Dysregulation of Apoptosis in Cancer

Reed, J. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2941 · Cited by 993

Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18.

Cleary, M. L., & Sklar, J. L. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.21.7439 · Cited by 955

Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2

Strasser, A., Harris, A. W., Bath, M. L., & Cory, S. (1990) · Nature · doi:10.1038/348331a0 · Cited by 915

Puma is an essential mediator of p53-dependent and -independent apoptotic pathways

Jeffers, J. R., Parganas, E., Lee, Y., Yang, C., Wang, J., Brennan, J. A., Maclean, K. H., Han, J., Chittenden, T., Ihle, J. N., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00244-7 · Cited by 880

Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18)

McDonnell, T. J., & Korsmeyer, S. J. (1991) · Nature · doi:10.1038/349254a0 · Cited by 872

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S., Huang, D. C. S., Xiong, H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 855

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

Wertz, I. E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W. N., Anderson, D. J., Helgason, E., Ernst, J. A., Eby, M., Liu, J., et al. (2011) · Nature · doi:10.1038/nature09779 · Cited by 801

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

Pan, R. A., Hogdal, L. J., Benito, J. M., Bucci, D. M., Han, L., Borthakur, G. M., Cortes, J. E., DeAngelo, D. J., Debose, L., Mu, H. H., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 734

BAX activation is initiated at a novel interaction site

Gavathiotis, E., Suzuki, M., Davis, M. L., Pitter, K., Bird, G. H., Katz, S. G., Tu, H.-C., Kim, H., Cheng, E. H.-Y., Tjandra, N., et al. (2008) · Nature · doi:10.1038/nature07396 · Cited by 700

bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia

Hanada, M., Delia, D., Aiello, A., Stadtmauer, E. A., & Reed, J. (1993) · Blood · doi:10.1182/blood.v82.6.1820.1820 · Cited by 673

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis

Nguyen, M., Marcellus, R. C., Roulston, A., Watson, M., Serfass, L., Madiraju, S. R. M., Goulet, D., Viallet, J., Bélec, L., Billot, X., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709443104 · Cited by 671

Use of Statins and the Risk of Death in Patients With Prostate Cancer

Yu, O. H. Y., Eberg, M., Benayoun, S., Aprikian, A. G., Batist, G., Suissa, S., & Azoulay, L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 661

SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction

Inuzuka, H., Shaik, S., Onoyama, I., Gao, D., Tseng, A., Maser, R. S., Zhai, B., Wan, L., Gutiérrez, A., Lau, A. W., et al. (2011) · Nature · doi:10.1038/nature09732 · Cited by 635

Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression

Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633

Bcl-xL Retrotranslocates Bax from the Mitochondria into the Cytosol

Edlich, F., Banerjee, S., Suzuki, M., Cleland, M. M., Arnoult, D., Wang, C., Neutzner, A., Tjandra, N., & Youle, R. J. (2011) · Cell · doi:10.1016/j.cell.2011.02.034 · Cited by 630

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737

Moore, V. D. G., Brown, J. R., Certo, M. V., Love, T. M., Novina, C. D., & Letai, A. G. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28281 · Cited by 617

Stepwise Activation of BAX and BAK by tBID, BIM, and PUMA Initiates Mitochondrial Apoptosis

Kim, H., Tu, H.-C., Ren, D., Takeuchi, O., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J.-D., & Cheng, E. H.-Y. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.030 · Cited by 600

Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers.

Krajewska, M., Krajewski, S., Epstein, J. I., Shabaik, A. S., Sauvageot, J., Song, K. B., Kitada, S., & Reed, J. C. (1996) · Europe PMC (PubMed Central) · Cited by 590

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

Chonghaile, T. N., Sarosiek, K. A., Vo, T.-T. T., Ryan, J. A., Tammareddi, A., Moore, V. D. G., Deng, J., Anderson, K. C., Richardson, P. G. G., Tai, Y., et al. (2011) · Science · doi:10.1126/science.1206727 · Cited by 588

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Rudin, C. M., Hann, C. L., Garon, E. B., de Oliveira, M. R., Bonomi, P., Camidge, D. R., Chu, Q. S.-C., Giaccone, G., Khaira, D. K., Ramalingam, S. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3090 · Cited by 576

PUMA mediates the apoptotic response to p53 in colorectal cancer cells

Yu, J., Wang, Z., Kinzler, K. W., Vogelstein, B., & Zhang, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2627984100 · Cited by 574

Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis

Czabotar, P. E., Westphal, D., Dewson, G., Ma, S., Hockings, C., Fairlie, W. D., Lee, E. F., Yao, S., Robin, A. Y., Smith, B. J., et al. (2013) · Cell · doi:10.1016/j.cell.2012.12.031 · Cited by 573

Membrane Binding by tBid Initiates an Ordered Series of Events Culminating in Membrane Permeabilization by Bax

Lovell, J. F., Billen, L. P., Bindner, S., Shamas‐Din, A., Fradin, C., Leber, B. F., & Andrews, D. W. (2008) · Cell · doi:10.1016/j.cell.2008.11.010 · Cited by 564

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

Ng, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2713 · Cited by 557

Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer

Catz, S. D., & Johnson, J. L. (2001) · Oncogene · doi:10.1038/sj.onc.1204926 · Cited by 538

BH3 Profiling Identifies Three Distinct Classes of Apoptotic Blocks to Predict Response to ABT-737 and Conventional Chemotherapeutic Agents

Deng, J., Carlson, N. E., Takeyama, K., Cin, P. D., Shipp, M. A., & Letai, A. G. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.001 · Cited by 528

Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance

Wei, G., Twomey, D., Lamb, J., Schlis, K. D., Agarwal, J., Stam, R. W., Opferman, J. T., Sallan, S. E., den Boer, M. L., Pieters, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.006 · Cited by 513

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

Costa, D. B., Halmos, B., Kumar, A., Schumer, S., Huberman, M. S., Boggon, T. J., Tenen, D. G., & Kobayashi, S. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040315 · Cited by 511

Bim is a suppressor of Myc-induced mouse B cell leukemia

Egle, A., Harris, A. W., Bouillet, P., & Cory, S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401471101 · Cited by 495

Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function

Luciano, F., Jacquel, A., Colosetti, P., Herrant, M., Cagnol, S., Pages, G., & Auberger, P. (2003) · Oncogene · doi:10.1038/sj.onc.1206792 · Cited by 477

BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program

Ren, D., Tu, H.-C., Kim, H., Wang, G. X., Bean, G. R., Takeuchi, O., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J.-D., & Cheng, E. H. Y. (2010) · Science · doi:10.1126/science.1190217 · Cited by 472

The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy

Kelly, P. N., & Strasser, A. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.17 · Cited by 455

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

Leverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440

Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E

Hsieh, A. C., Costa, M., Zollo, O., Davis, C., Feldman, M. E., Testa, J. R., Meyuhas, O., Shokat, K. M., & Ruggero, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.021 · Cited by 434

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells

Derenne, S., Monia, B. P., Dean, N. M., Taylor, J. K., Rapp, M.-J., Harousseau, J., Bataille, R., & Amiot, M. (2002) · Blood · doi:10.1182/blood.v100.1.194 · Cited by 429

FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal

You, H., Pellegrini, M., Tsuchihara, K., Yamamoto, K., Häcker, G. A., Erlacher, M., Villunger, A., & Mak, T. W. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060353 · Cited by 429

BID regulation by p53 contributes to chemosensitivity

Sax, J. K., Fei, P., Murphy, M. E., Bernhard, E., Korsmeyer, S. J., & El-Deiry, W. S. (2002) · Nature Cell Biology · doi:10.1038/ncb866 · Cited by 420

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

She, Q., Solit, D. B., Ye, Q., O'Reilly, K. E., Lobo, J. M., & Rosen, N. X. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.006 · Cited by 416

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

Montero, J., Sarosiek, K. A., DeAngelo, J. D., Maertens, O., Ryan, J., Ercan, D., Piao, H., Horowitz, N. S., Berkowitz, R. S., Matulonis, U., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.042 · Cited by 378

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

Corcoran, R. B., Cheng, K. A., Hata, A. N., Faber, A. C., Ebi, H., Coffee, E. M., Greninger, P., Brown, R. D., Godfrey, J. T., Cohoon, T. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.007 · Cited by 377

Myeloid cell factor–1 is a critical survival factor for multiple myeloma

Zhang, B., Gojo, I., & Fenton, R. G. (2002) · Blood · doi:10.1182/blood.v99.6.1885 · Cited by 372

Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse

Kaufmann, S. H., Karp, J. E., Svingen, P. A., Krajewski, S., Burke, P. J., Gore, S. D., & Reed, J. C. (1998) · Blood · doi:10.1182/blood.v91.3.991.991_991_1000 · Cited by 368

Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML

Vo, T.-T. T., Ryan, J. A., Carrasco, R. D., Neuberg, D. S., Rossi, D. J., Stone, R. M., DeAngelo, D. J., Frattini, M. G., & Letai, A. G. (2012) · Cell · doi:10.1016/j.cell.2012.08.038 · Cited by 356

Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics

Cragg, M. S., Kuroda, J., Puthalakath, H., Huang, D. C. S., & Strasser, A. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040316 · Cited by 346

Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic

Kuroda, J., Puthalakath, H., Cragg, M. S., Kelly, P. N., Bouillet, P., Huang, D. C. S., Kimura, S. H., Ottmann, O. G., Druker, B. J., Villunger, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606176103 · Cited by 339

Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival

Wuillème‐Toumi, S., Robillard, N., Gomez‐Bougie, P., Moreau, P., Gouill, S. L., Avet‐Loiseau, H., Harousseau, J., Amiot, M., & Bataille, R. (2005) · Leukemia · doi:10.1038/sj.leu.2403784 · Cited by 337

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas

Gong, Y., Somwar, R., Politi, K. A., Balak, M. N., Chmielecki, J., Jiang, X., & Pao, W. J. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040294 · Cited by 330

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

Faber, A. C., Li, D., Song, Y., Liang, M.-C., Yeap, B. Y., Bronson, R. T., Lifshits, E., Chen, Z., Maira, S.-M., García-Echeverría, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905056106 · Cited by 319

Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design

Friberg, A., Vigil, D., Zhao, B., Daniels, R. N., Burke, J. P., García-Barrantes, P. M., Camper, D. V., Chauder, B. A., Lee, T., Olejniczak, E. T., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301448p · Cited by 318

Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM

Tagawa, H., Karnan, S., Suzuki, R., Matsuo, K., Zhang, X., Ota, A., Morishima, Y., Nakamura, S., & Seto, M. (2004) · Oncogene · doi:10.1038/sj.onc.1208300 · Cited by 315

Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations

Mukohara, T., Engelman, J. A., Hanna, N. H., Yeap, B. Y., Kobayashi, S. S., Lindeman, N. I., Halmos, B., Pearlberg, J., Tsuchihashi, Z., Cantley, L. C., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji238 · Cited by 314

CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene.

Ohtani‐Fujita, N., Fujita, T., Aoike, A., Osifchin, N. E., Robbins, P. D., & Sakai, T. (1993) · PubMed · Cited by 311

BH3-Triggered Structural Reorganization Drives the Activation of Proapoptotic BAX

Gavathiotis, E., Reyna, D. E., Davis, M. L., Bird, G. H., & Walensky, L. D. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.10.019 · Cited by 310

Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells

Essafi, A., de Mattos, S. F., Hassen, Y., Soeiro, I., Mufti, G. J., Thomas, N. S. B., Medema, R. H., & Lam, E. W. ‐. (2005) · Oncogene · doi:10.1038/sj.onc.1208421 · Cited by 298

A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy

Placzek, W. J., Wei, J., Kitada, S., Zhai, D., Reed, J. C., & Pellecchia, M. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.18 · Cited by 296

FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD–specific STAT5 activation

Yoshimoto, G., Miyamoto, T., Jabbarzadeh‐Tabrizi, S., Iino, T., Rocnik, J. L., Kikushige, Y., Mori, Y., Shima, T., Iwasaki, H., Takenaka, K., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196055 · Cited by 285

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors

Faber, A. C., Corcoran, R. B., Ebi, H., Sequist, L. V., Waltman, B. A., Chung, E., Incio, J., Digumarthy, S. R., Pollack, S. F., Song, Y., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0106 · Cited by 283

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

O'Brien, S. M., Claxton, D. F., Crump, M., Faderl, S. H., Kipps, T. J., Keating, M. J., Viallet, J., & Cheson, B. D. (2008) · Blood · doi:10.1182/blood-2008-02-137943 · Cited by 274

Bad -deficient mice develop diffuse large B cell lymphoma

Ranger, A. M., Zha, J., Harada, H., Datta, S. R., Danial, N. N., Gilmore, A. P., Kutok, J. L., Beau, M. M. L., Greenberg, M. E., & Korsmeyer, S. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533446100 · Cited by 267

BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response

Sarosiek, K. A., Chi, X., Bachman, J. A., Sims, J. J., Montero, J., Patel, L., Flanagan, A., Andrews, D. W., Sorger, P. K., & Letai, A. G. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.048 · Cited by 252

‘Seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737

Lin, X., Morgan-Lappe, S. E., Huang, X., Li, L., Zakula, D., Vernetti, L. A., Fesik, S. W., & Shen, Y. (2006) · Oncogene · doi:10.1038/sj.onc.1210166 · Cited by 250

Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index

Callagy, G. M., Pharoah, P. D. P., Pinder, S. E., Hsu, F. D., Nielsen, T. O., Ragaz, J., Ellis, I. O., Huntsman, D. D., & Caldas, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2719 · Cited by 235

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

Costa, C., Molina, M. A., Drozdowskyj, A., Giménez-Capitán, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2233 · Cited by 229

BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia

Moore, V. D. G., Schlis, K. D., Sallan, S. E., Armstrong, S. A., & Letai, A. G. (2007) · Blood · doi:10.1182/blood-2007-06-098012 · Cited by 222

Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells

Song, L., Coppola, D., Livingston, S., Cress, W. D., & Haura, E. B. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.3.1496 · Cited by 217

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

Cragg, M. S., Jansen, E. S., Cook, M., Harris, C., Strasser, A., & Scott, C. L. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35437 · Cited by 207

20 years studying p53 functions in genetically engineered mice

Donehower, L. A., & Lozano, G. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2731 · Cited by 196

Myeloid Cell Leukemia-1 Inversely Correlates with Glycogen Synthase Kinase-3β Activity and Associates with Poor Prognosis in Human Breast Cancer

Ding, Q., He, X., Xia, W., Hsu, J.-M., Chen, C., Li, L., Lee, D., Yang, J.-Y., Xie, X., Liu, J.-C., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1788 · Cited by 194

Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1

Wang, Y. F., Jiang, C. C., Avery‐Kiejda, K. A., Gillespie, S., Zhang, X. D., & Hersey, P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0665 · Cited by 194

MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes

Zhou, P., Levy, N. B., Xie, H., Qian, L., Lee, C. G., Gascoyne, R. D., & Craig, R. W. (2001) · Blood · doi:10.1182/blood.v97.12.3902 · Cited by 192

βTrCP- and Rsk1/2-Mediated Degradation of BimEL Inhibits Apoptosis

Dehan, E., Bassermann, F. C., Guardavaccaro, D., Vasiliver-Shamis, G., Cohen, M. S., Lowes, K. N., Dustin, M. L., Huang, D. C. S., Taunton, J., & Pagano, M. (2009) · Molecular Cell · doi:10.1016/j.molcel.2008.12.020 · Cited by 188

The role of BH3-only protein Bim extends beyond inhibiting Bcl-2–like prosurvival proteins

Mérino, D., Giam, M., Hughes, P., Siggs, O. M., Heger, K., O’Reilly, L. A., Adams, J. M., Strasser, A., Lee, E. F., Fairlie, W. D., et al. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200905153 · Cited by 185

Small molecule Mcl-1 inhibitors for the treatment of cancer

Belmar, J., & Fesik, S. W. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.08.003 · Cited by 181

BCL-2 in prostate cancer: A minireview

Catz, S. D., & Johnson, J. L. (2003) · APOPTOSIS · doi:10.1023/a:1021692801278 · Cited by 178

ERK1/2‐dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl‐1 and Bcl‐xL

Ewings, K. E., Hadfield‐Moorhouse, K., Wiggins, C. M., Wickenden, J. A., Balmanno, K., Gilley, R., Degenhardt, K., White, E., & Cook, S. J. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601723 · Cited by 176

Antiapoptotic BCL-2 is required for maintenance of a model leukemia

Letai, A. G., Sorcinelli, M. D., Beard, C., & Korsmeyer, S. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.011 · Cited by 175

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

Costa, D. B., Nguyen, K.-S. H., Cho, B. C., Sequist, L. V., Jackman, D. M., Riely, G. J., Yeap, B. Y., Halmos, B., Kim, J. H., Jänne, P. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1455 · Cited by 171

Still embedded together binding to membranes regulates Bcl-2 protein interactions

Leber, B. F., Lin, J., & Andrews, D. W. (2010) · Oncogene · doi:10.1038/onc.2010.283 · Cited by 167

Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

Zhang, H., Guttikonda, S. R., Roberts, L., Uziel, T., Semizarov, D., Elmore, S. W., Leverson, J. D., & Lam, L. T. (2010) · Oncogene · doi:10.1038/onc.2010.559 · Cited by 164

Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity

Bruncko, M., Wang, L., Sheppard, G. S., Phillips, D. C., Tahir, S. K., Xue, J., Erickson, S., Fidanze, S., Fry, E., Hasvold, L., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501258m · Cited by 164

Proapoptotic BH3-Only BCL-2 Family Protein BIM Connects Death Signaling from Epidermal Growth Factor Receptor Inhibition to the Mitochondrion

Deng, J., Shimamura, T., Perera, S. A., Carlson, N. E., Cai, D. D., Shapiro, G. I., Wong, K., & Letai, A. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1961 · Cited by 160

Immunohistochemical Analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 Expression in Pancreatic Cancers

Miyamoto, Y., Hosotani, R., Wada, M., Lee, J.-U., Koshiba, T., Fujimoto, K., Tsuji, S., Nakajima, S., Doi, R., Kato, M., et al. (1999) · Oncology · doi:10.1159/000011933 · Cited by 159

Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice

Jäger, R., Herzer, U., Schenkel, J., & Weiher, H. (1997) · Oncogene · doi:10.1038/sj.onc.1201353 · Cited by 159

EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition

Nakagawa, T., Takeuchi, S., Yamada, T., Ebi, H., Sano, T., Nanjo, S., Ishikawa, D., Sato, M., Hasegawa, Y., Sekido, Y., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3479 · Cited by 158

Direct activation of full-length proapoptotic BAK

Leshchiner, E. S., Braun, C. R., Bird, G. H., & Walensky, L. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214313110 · Cited by 157

Roles of Bim in Apoptosis of Normal and Bcr-Abl-Expressing Hematopoietic Progenitors

Kuribara, R., Honda, H., Matsui, H., Shinjyo, T., Inukai, T., Sugita, K., Nakazawa, S., Hirai, H., Ozawa, K., & Inaba, T. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.14.6172-6183.2004 · Cited by 156

Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity.

Bhargava, V., Kell, D., van de Rijn, M., & Warnke, R. A. (1994) · PubMed Central · Cited by 155

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer

Takezawa, K., Okamoto, I., Nishio, K., Janne, P. A., & Nakagawa, K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2798 · Cited by 141

TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma

Corcoran, R. B., Rothenberg, S. M., Hata, A. N., Faber, A. C., Piris, A., Nazarian, R. M., Brown, R. D., Godfrey, J. T., Winokur, D., Walsh, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005753 · Cited by 140

Melanoma Proliferation and Chemoresistance Controlled by the DEK Oncogene

Khodadoust, M. S., Verhaegen, M. E., Kappes, F., Riveiro‐Falkenbach, E., Cigudosa, J. C., Kim, D. S. L., Chinnaiyan, A. M., Markovitz, D. M., & Soengas, M. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1063 · Cited by 136

Growth- and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells.

Núñez, G., Seto, M., Seremetis, S. V., Ferrero, D., Grignani, F., Korsmeyer, S. J., & Dalla‐Favera, R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.12.4589 · Cited by 131

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

Faber, A. C., Farago, A. F., Costa, C., Dastur, A., Gomez-Caraballo, M., Robbins, R., Wagner, B. L., Rideout, W. M., Jakubik, C. T., Ham, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411848112 · Cited by 127 · cited 2×

Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa

Inoue, S., Riley, J., Gant, T. W., Dyer, M. J. S., & Cohen, G. M. (2007) · Leukemia · doi:10.1038/sj.leu.2404760 · Cited by 124

mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1

Faber, A. C., Coffee, E. M., Costa, C., Dastur, A., Ebi, H., Hata, A. N., Yeo, A. T., Edelman, E. J., Song, Y., Tam, A. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0315 · Cited by 124

BI-97C1, an Optically Pure Apogossypol Derivative as Pan-Active Inhibitor of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins

Wei, J., Stebbins, J. L., Kitada, S., Dash, R., Placzek, W. J., Rega, M. F., Wu, B., Cellitti, J. F., Zhai, D., Yang, L., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1001265 · Cited by 123

PUMA and BIM Are Required for Oncogene Inactivation–Induced Apoptosis

Bean, G. R., Ganesan, Y. T., Dong, Y., Takeda, S., Liu, H., Chan, P. M., Huang, Y., Chodosh, L. A., Zambetti, G. P., Hsieh, J. J.-D., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2003483 · Cited by 123

Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia

Xiang, Z., Luo, H., Payton, J. E., Cain, J., Ley, T. J., Opferman, J. T., & Tomasson, M. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39964 · Cited by 120

Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma

Richter, J. Á., Robles, E. F., Fresquet, V., Beltrán, E., Rullan, A., Agirre, X., Calasanz, M. J., Panizo, C., Richter, J. Á., Hernández‐Rivas, J. M., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268003 · Cited by 118

Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.

Bachmann, P., Piazza, R., Janes, M. E., Wong, N., Davies, C., Mogavero, A., Bhadri, V., Szymanska, B., Geninson, G., Magistroni, V., et al. (2010) · Blood · doi:10.1182/blood-2010-05-284968 · Cited by 118

The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment

Elkholi, R., Floros, K. V., & Chipuk, J. E. (2011) · Genes & Cancer · doi:10.1177/1947601911417177 · Cited by 114

Differences in the Mechanisms of Proapoptotic BH3 Proteins Binding to Bcl-XL and Bcl-2 Quantified in Live MCF-7 Cells

Aranovich, A., Liu, Q., Collins, T., Geng, F., Dixit, S., Leber, B. F., & Andrews, D. W. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.01.030 · Cited by 103

Evaluation and critical assessment of putative MCL-1 inhibitors

Varadarajan, S., Vogler, M., Butterworth, M., Dinsdale, D. D., Walensky, L. D., & Cohen, G. M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.79 · Cited by 101

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer

Paik, P. K., Rudin, C. M., Pietanza, M. C., Brown, A. B., Rizvi, N. A., Takebe, N., Travis, W. D., James, L. P., Ginsberg, M. S., Juergens, R. A., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.05.005 · Cited by 100

MCL-1 expression in B-cell non-Hodgkin’s lymphomas

Cho‐Vega, J. H., Rassidakis, G. Z., Admirand, J. H., Oyarzo, M. P., Ramalingam, P., Paraguya, A., McDonnell, T. J., Amin, H. M., & Medeiros, L. J. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.04.018 · Cited by 97

Low-Level Expression of Proapoptotic Bcl-2–Interacting Mediator in Leukemic Cells in Patients with Chronic Myeloid Leukemia: Role of BCR/ABL, Characterization of Underlying Signaling Pathways, and Reexpression by Novel Pharmacologic Compounds

Aichberger, K. J., Mayerhofer, M., Krauth, M., Vales, A., Kondo, R., Derdak, S. V., Pickl, W. F., Selzer, E., Deininger, M. W., Druker, B. J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0972 · Cited by 93

Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia

José‐Eneriz, E. S., Agirre, X., Jiménez‐Velasco, A., Cordeu, L., Martín, V., Arqueros, V., Gárate, L., Fresquet, V., Cervantes, F., Martinez-Climent, J. A., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.005 · Cited by 91

PUMA expression is significantly reduced in human cutaneous melanomas

Karst, A. M., Dai, D. L., Martinka, M., & Li, G. (2004) · Oncogene · doi:10.1038/sj.onc.1208374 · Cited by 91

Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK

McCoy, F. P. G., Hurwitz, J. L., McTavish, N., Paul, I., Barnes, C., O’Hagan, B. M. G., Odrzywol, K., Murray, J. T., Longley, D. B., McKerr, G., et al. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.86 · Cited by 89

Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis

Parikh, S. A., Kantarjian, H. M., Schimmer, A. D., Walsh, W., Asatiani, E., El‐Shami, K., Winton, E. F., & Verstovšek, S. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.059 · Cited by 89

The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer

Zhao, M., Zhang, Y., Cai, W., Li, J., Zhou, F., Cheng, N., Ren, R., Zhao, C., Li, X., Ren, S., et al. (2014) · Cancer · doi:10.1002/cncr.28725 · Cited by 87

The Role of BRAF Mutation and p53 Inactivation during Transformation of a Subpopulation of Primary Human Melanocytes

Yu, H., McDaid, R., Lee, J., Possik, P. A., Li, L., Kumar, S. M., Elder, D. E., Belle, P. A. V., Gimotty, P. A., Guerra, M., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081057 · Cited by 85

Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein

Petros, A. M., Swann, S. L., Song, D., Swinger, K. K., Park, C., Zhang, H., Wendt, M. D., Kunzer, A. R., Souers, A. J., & Sun, C. C. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.02.010 · Cited by 83

Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

Tan, N., Wong, M., Nannini, M., Hong, R., Lee, L. B., Price, S., Williams, K. R., Savy, P., Yue, P., Sampath, D., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0949 · Cited by 80

Mitogen-Activated Protein Kinase Inhibition Induces Translocation of Bmf to Promote Apoptosis in Melanoma

VanBrocklin, M. W., Verhaegen, M. E., Soengas, M. S., & Holmen, S. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3934 · Cited by 77

Gene Expression-Based Chemical Genomics Identifies Potential Therapeutic Drugs in Hepatocellular Carcinoma

Chen, M., Yang, W.-L. R., Lin, K., Liu, C.-H., Liu, Y.-W., Huang, K., Chang, P. M., Lai, J.-M., Hsu, C.-N., Chao, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027186 · Cited by 75

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

Hata, A. N., Yeo, A., Faber, A. C., Lifshits, E., Chen, Z., Cheng, K. A., Walton, Z., Sarosiek, K. A., Letai, A., Heist, R. S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3728 · Cited by 74

Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation

Isobe, K., Hata, Y., Tochigi, N., Kaburaki, K., Kobayashi, H., Makino, T., Otsuka, H., Sato, F., Ishida, F., Kikuchi, N., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000125 · Cited by 70

Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM

Wickenden, J. A., Jin, H., Johnson, M., Gillings, A. S., Newson, C., Austin, M. J., Chell, S. D., Balmanno, K., Pritchard, C. A., & Cook, S. J. (2008) · Oncogene · doi:10.1038/onc.2008.335 · Cited by 69

Pan-Mammalian Target of Rapamycin (mTOR) Inhibitor AZD8055 Primes Rhabdomyosarcoma Cells for ABT-737-induced Apoptosis by Down-regulating Mcl-1 Protein

Preuß, E., Hugle, M., Reimann, R., Schlecht, M., & Fulda, S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.495986 · Cited by 66

Apoptosis In Targeted Therapy Responses

Faber, A. C., Ebi, H., Costa, C., & Engelman, J. A. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00016-6 · Cited by 63

ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.

Seymour, J. F., Davids, M. S., Pagel, J. M., Kahl, B. S., Wierda, W. G., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Huang, D. C. S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.7015 · Cited by 58

Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance

Serasinghe, M. N., Missert, D. J., Asciolla, J. J., Podgrabinska, S., Wieder, S. Y., Izadmehr, S., Belbin, G. M., Skobe, M., & Chipuk, J. E. (2014) · Oncogene · doi:10.1038/onc.2014.21 · Cited by 58

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance

Sale, M. J., & Cook, S. J. (2013) · Biochemical Journal · doi:10.1042/bj20121212 · Cited by 58

Fatal Acute Lymphoblastic Leukemia in Mice Transgenic for B Cell-Restricted bcl-xL and c- myc

Swanson, P. J., Kuslak, S. L., Wei, F., Tze, L. E., Gaffney, P. M., Selby, S. A., Hippen, K. L., Núñez, G., Sidman, C. L., & Behrens, T. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.6684 · Cited by 55

Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex

Piazza, R., Magistroni, V., Mogavero, A., Andreoni, F., Ambrogio, C., Chiarle, R., Mologni, L., Bachmann, P. S., Lock, R. B., Collini, P., et al. (2013) · Neoplasia · doi:10.1593/neo.121784 · Cited by 51

Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma

Müller, A., Zang, C., Chumduri, C., Dörken, B., Daniel, P. T., & Scholz, C. W. (2013) · International Journal of Cancer · doi:10.1002/ijc.28206 · Cited by 51

Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics

Frederick, D. T., Fragomeni, R. A. S., Schalck, A. P., Ferreiro-Neira, I., Hoff, T., Cooper, Z. A., Haq, R., Panka, D. J., Kwong, L. N., Davies, M. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101286 · Cited by 50

Sabutoclax (BI97C1) and BI112D1, Putative Inhibitors of MCL-1, Induce Mitochondrial Fragmentation Either Upstream of or Independent of Apoptosis

Varadarajan, S., Butterworth, M., Wei, J., Pellecchia, M., Dinsdale, D. D., & Cohen, G. M. (2013) · Neoplasia · doi:10.1593/neo.13230 · Cited by 48

Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies

Linden, M. A., Kirchhof, N., Carlson, C. S., & Ness, B. V. (2003) · Blood · doi:10.1182/blood-2003-10-3399 · Cited by 47

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small-Cell Lung Cancer

Lee, J., Lin, Y., Hsu, W., Chen, H., Chang, Y., Yu, C., Shih, J., Lin, C., Chen, K., Ho, C., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000238 · Cited by 44

Differences underlying EGFR and HER2 oncogene addiction

Faber, A. C., Wong, K., & Engelman, J. A. (2010) · Cell Cycle · doi:10.4161/cc.9.5.11096 · Cited by 41

Obatoclax Mesylate, a Pan–Bcl-2 Inhibitor, in Combination with Docetaxel in a Phase 1/2 Trial in Relapsed Non–Small-Cell Lung Cancer

Chiappori, A., Williams, C. C., Northfelt, D., Adams, J. W., Malik, S. M., Edelman, M. J., Rosen, P. J., Echo, D. A. V., Berger, M. S., & Haura, E. B. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000027 · Cited by 38

Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells

Katz, S. G., LaBelle, J. L., Meng, H., Valeriano, R. P., Fisher, J. K., Sun, H. H., Rodig, S. J., Kleinstein, S. H., & Walensky, L. D. (2013) · Blood · doi:10.1182/blood-2013-04-499079 · Cited by 36

A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib

Augis, V., Airiau, K., Josselin, M., Turcq, B., Mahon, F.-X., & Belloc, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078582 · Cited by 35

Can the analysis of BH3-only protein knockout mice clarify the issue of ‘direct versus indirect’ activation of Bax and Bak?

Villunger, A., Labi, V., Bouillet, P., Adams, J. M., & Strasser, A. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.100 · Cited by 32

Targeting the Regulatory Machinery of BIM for Cancer Therapy

Harada, H., & Grant, S. (2012) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v22.i2.40 · Cited by 30

c-Cbl is not required for ERK1/2-dependent degradation of BimEL

Wiggins, C. M., Band, H., & Cook, S. J. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.08.008 · Cited by 26

The BCL 2L11 ( BIM ) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients

Katagiri, S., Umezu, T., Ohyashiki, J. H., & Ohyashiki, K. (2012) · British Journal of Haematology · doi:10.1111/bjh.12111 · Cited by 19

The C/EBP Homologous Protein (CHOP) Transcription Factor Functions in Endoplasmic Reticulum Stress-Induced Apoptosis and Microbial Infection

Hu, H., Tian, M., Ding, C., & Yu, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03083 · Cited by 1,177

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985

Tumor biomarkers for diagnosis, prognosis and targeted therapy

Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 836

Precision medicine for cancer with next-generation functional diagnostics

Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570

Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer

Liu, G., Pei, F., Yang, F., Li, L., Amin, A. D., Liu, S., Buchan, J. R., & Cho, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020367 · Cited by 430

The role of BCL-2 family proteins in regulating apoptosis and cancer therapy

Qian, S., Wei, Z., Yang, W., Huang, J., Yang, Y., & Wang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.985363 · Cited by 1,011

Targeting BCL-2 regulated apoptosis in cancer

Campbell, K. J., & Tait, S. W. G. (2018) · Open Biology · doi:10.1098/rsob.180002 · Cited by 564

Biomarkers of Therapeutic Response to BCL2 Antagonists in Cancer

Lam, L. T., Zhang, H., & Chyla, B. (2012) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-012-0003-6 · Cited by 13

Cell Death and Targeted Cancer Therapies

(2022) · Frontiers research topics · doi:10.3389/978-2-88976-684-0

Diagnosing and exploiting cancer's addiction to blocks in apoptosis

Letai, A. G. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2297 · Cited by 590